HealthcareServices

Strong CAGR to Propel in the Neuroendocrine Carcinoma Market and Beyond upto $2.33 Billion by 2029

June 26, 2025 by Marketing Posting

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

#How Fast Is The Neuroendocrine Carcinoma Market Expected to Grow Between 2025 And 2029?#_x000D_

In the past few years, there has been a significant increase in the size of the neuroendocrine carcinoma market. This market is projected to grow from a value of $1.63 billion in 2024 to $1.76 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.7%. The historical growth of this market can be traced back to the burgeoning imaging sector, increased prevalence of neuroendocrine tumors, substantial investments, expanding government initiatives, and heightened demand for effective neuroendocrine tumor treatments._x000D_

_x000D_

A significant increase in the neuroendocrine carcinoma market size is anticipated in the coming years, with projections estimating a rise to $2.33 billion by 2029. This growth, which indicates a compound annual growth rate (CAGR) of 7.3%, can be largely attributed to factors such as the heightened incidence of cancer, a growing rate of product approvals, the escalating usage of advanced diagnostic imaging techniques, the development of targeted therapies, and an increase in available diagnosis and treatment options. Some prevalent trends during the forecast period involve the evolution of diagnostic technology, improvement in imaging technologies, targeted treatment strategies, advancements in managing neuroendocrine tumors, and progressing targeted therapies and immunotherapies._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp_x000D_

_x000D_

#Which Primay Drivers Are Accelerating Growth in the Neuroendocrine Carcinoma Market?#_x000D_

The escalation in targeted therapies is predicted to spur the neuroendocrine carcinoma market expansion. These therapies are specifically made to accurately target and impede the molecular or genetic changes responsible for a disease, often cancer. Factors like specificity in treating individual genetic mutations, progress in personalized medicine, and enhanced patient outcomes with minimal side effects spur the demand for these therapies. The nature of neuroendocrine carcinoma facilitates the creation of targeted therapies that cater specifically to the tumour’s genetic and biochemical profile, leading to improved treatment precision and efficacy. For instance, as per a report from the American Society of Gene & Cell Therapy (ASGCT), a US professional membership body, and Citeline, a US provider of drugs and devices, in July 2023, there were 247 gene therapies in Phase II at the end of Q1 2023. However, this number saw a 5% surge reaching 260 by Q2’s end. Hence, the rise in targeted therapies is stimulating the neuroendocrine carcinoma market’s growth._x000D_

_x000D_

#Which Primary Segments of the Neuroendocrine Carcinoma Market Are Driving Growth and Industry Transformations?#_x000D_

The neuroendocrine carcinoma market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma_x000D_

2) By Diagnostic Tools: Imaging, Biopsy, Serology_x000D_

3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments_x000D_

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers_x000D_

_x000D_

Subsegments:_x000D_

1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors_x000D_

2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors_x000D_

3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma_x000D_

4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21229&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Neuroendocrine Carcinoma Market?# Market?#_x000D_

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Technological Trends Are Reshaping the Neuroendocrine Carcinoma Industry Dynamics?#_x000D_

Leading firms in the neuroendocrine carcinoma market are heavily investing in the development of superior treatments like targeted radiopharmaceutical therapy, aimed at enhancing the accuracy of treatment and patient recovery results. This therapy uses radioactive molecules that are developed to specifically aim at and radiate cancer cells, therefore restricting damage to healthy tissue. Abdera Therapeutics Inc., a Biotech firm based in Canada for example, obtained an orphan drug designation from the FDA for ABD-147, meant for neuroendocrine carcinoma treatment, in September 2024. The drug is engineered to selectively aim at tumors expressing the DLL3 protein, which is often enhanced in aggressive neuroendocrine cancers like small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This recognition brings with it notable advancement benefits such as tax credit for clinical trials and the possibility of market exclusivity, making ABD-147 a potential future contender in this specific oncology field._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Neuroendocrine Carcinoma Market?#_x000D_

Neuroendocrine carcinoma (NEC) refers to a rare and aggressive type of cancer that originates in neuroendocrine cells, which have traits of both nerve cells and hormone-producing cells. They are used for identifying and treating tumors that can develop in various organs, including the lungs, pancreas, and gastrointestinal tract, often requiring a combination of surgery, chemotherapy, and targeted therapies._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21229_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_